Calgary precision healthcare company Syantra has raised a $6.8 million Series A fundraising round led by a consortium group of doctors in Canada through Rejuvenation Health which sees the test as an excellent element of its offering to women through its concierge medicine practice.
Included in Syantra’s Series A fundraising is being the first recipient with Plug and Play Alberta.
Syantra DX | Breast Cancer is Syantra’s flagship product. Its technology brings a new method of detecting breast cancer to market through a suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result, representing an early entrant into the emerging molecular diagnostic sector.
“This is a major milestone for our company,” states Bob Shepherd, President and Chief Executive Officer at Syantra. “Capturing the attention and securing funding from the calibre of investors we are proud to call partners is a testament to our groundbreaking technology that is changing the way cancer is detected and treated.”
“There are a lot of exciting things happening in Alberta, and not only are we watching, but we want to be active participants,” Shepherd states. “Securing Series A funding allows us to progress the commercialization of our Syantra DX platform, starting with breast cancer,” continues Shepherd.
“This includes scaling up our base lab facility in Calgary to be able to increase our capacity to process up to 2.5 times more blood tests by spring, as well as progressing our clinical study work with targeted cancers in our research pipeline.”